If you have been reading about dual agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection |
| Solubility | Soluble in aqueous buffer | Lipophilic chain lowers pure-water solubility |
| Long-term storage | -20 degrees Celsius or lower | With desiccant, protected from light |
| Short-term storage | 2 to 8 degrees Celsius | For dissolved aliquots |
| Typical purity method | Reversed-phase HPLC | Ultraviolet detection, often with mass confirmation |
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
==== Australia ==== In Australia, MDMA was rescheduled on 1 July 2023 as a schedule 8 substance (available on prescription) when used in the treatment of PTSD, while remaining a schedule 9 substance (prohibited) for all other uses. For the treatment of PTSD, MDMA can only be prescribed by psychiatrists with specific training and authorisation. In 1986, MDMA was declared an illegal substance because of its allegedly harmful effects and potential for misuse. Any non-authorised sale, use or manufacture is strictly prohibited by law. Permits for research uses on humans must be approved by a recognized ethics committee on human research. In Western Australia under the Misuse of Drugs Act 1981 4.0g of MDMA is the amount required determining a court of trial, 2.0g is considered a presumption with intent to sell or supply and 28.0g is considered trafficking under Australian law. The Australian Capital Territory passed legislation to decriminalise the possession of small amounts of MDMA, which took effect in October 2023.
This lengthy procedure prevents the researcher from spontaneous identifications of a few interesting spots from a single gel as well as the need to operate the systems at full capacity. The resulting amount of data from the subsequent automated MS analysis is another problem of high throughput systems as their quality is often questionable and the evaluation of these data takes significantly longer than the collection.
=== 1970s === Following Giant-Size X-Men, the X-Men comic was revived with issue #94 (August 1975), drawn by Cockrum and written by Chris Claremont. Wolverine is initially overshadowed by the other characters, although he creates tension in the team as he is attracted to Cyclops' girlfriend, Jean Grey. As the series progressed, Claremont considered dropping Wolverine from the comic; Cockrum's successor, artist John Byrne, championed the character, later explaining that as a Canadian himself he did not want to see the only Canadian character dropped. Byrne modeled his rendition of Wolverine on actor Paul D'Amato, who played Dr. Hook in the sports film Slap Shot (1977). Cockrum introduced another costume for Wolverine in the final issue of his run, but it was dropped at the start of Byrne's run because he found it difficult to draw. Wolverine was first drawn without his mask in X-Men #98 (April 1976); his distinctive hairstyle became one of his trademarks. The same issue also established that Wolverine's claws are an integrated part of his anatomy. X-Men #100 introduces the "fastball special", a combat maneuver in which the super-strong Colossus throws Wolverine at a distance as if he were a projectile weapon; this tactic recurs in many future battles. Stories of the late 1970s establish Wolverine's murky past and unstable nature, which he battles to keep in check. Wolverine's name was revealed as "Logan" in X-Men #103 (February 1977); Claremont drew inspiration from Canada's Mount Logan, liking "the idea [of] the tallest mountain being the name of the shortest character".
DNA methylation is a widespread mechanism for epigenetic influence on gene expression and is seen in bacteria and eukaryotes and has roles in heritable transcription silencing and transcription regulation. Methylation most often occurs on a cytosine (see Figure). Methylation of cytosine primarily occurs in dinucleotide sequences where a cytosine is followed by a guanine, a CpG site. The number of CpG sites in the human genome is about 28 million. Depending on the type of cell, about 70% of the CpG sites have a methylated cytosine. Methylation of cytosine in DNA has a major role in regulating gene expression. Methylation of CpGs in a promoter region of a gene usually represses gene transcription while methylation of CpGs in the body of a gene increases expression. TET enzymes play a central role in demethylation of methylated cytosines. Demethylation of CpGs in a gene promoter by TET enzyme activity increases transcription of the gene.
=== Death === De Duve died on 4 May 2013, at his home in Nethen, Belgium, aged 95. He decided to end his life by legal euthanasia, performed by two doctors and in the presence of his four children. He had been long suffering from cancer and atrial fibrillation, and his health problems were exacerbated by a recent fall in his home. De Duve was cremated as he had willed, and his ashes were distributed among family members and friends.
Sources: en.wikipedia.org
=== EC 1.14.19 With oxidation of a pair of donors resulting in the reduction of O2 to two molecules of water === EC 1.14.19.1: stearoyl-CoA 9-desaturase EC 1.14.19.2: stearoyl-[acyl-carrier-protein] 9-desaturase EC 1.14.19.3: linoleoyl-CoA desaturase EC 1.14.19.4: acyl-lipid (11-3)-desaturase EC 1.14.19.5: acyl-CoA 11-(Z)-desaturase EC 1.14.19.6: acyl-CoA (9+3)-desaturase EC 1.14.19.7: Now EC 1.11.1.23, (S)-2-hydroxypropylphosphonic acid epoxidase EC 1.14.19.8: pentalenolactone synthase EC 1.14.19.9: tryptophan 7-halogenase EC 1.14.19.10: icosanoyl-CoA 5-desaturase EC 1.14.19.11: acyl-[acyl-carrier-protein] 4-desaturase EC 1.14.19.12: acyl-lipid ω-(9-4) desaturase EC 1.14.19.13: acyl-CoA 15-desaturase EC 1.14.19.14: linoleoyl-lipid Δ9 conjugase EC 1.14.19.15: (11Z)-hexadec-11-enoyl-CoA conjugase EC 1.14.19.16: linoleoyl-lipid Δ12 conjugase (11E,13Z-forming) EC 1.14.19.17: sphingolipid 4-desaturase EC 1.14.19.18: sphingolipid 8-(E)-desaturase EC 1.14.19.19: sphingolipid 10-desaturase EC 1.14.19.20: Δ7-sterol 5(6)-desaturase EC 1.14.19.21: cholesterol 7-desaturase EC 1.14.19.22: acyl-lipid ω-6 desaturase (cytochrome b5) EC 1.14.19.23: acyl-lipid (n+3)-(Z)-desaturase (ferredoxin) EC 1.14.19.24: acyl-CoA 11-(E)-desaturase EC 1.14.19.25: acyl-lipid ω-3 desaturase (cytochrome b5) EC 1.14.19.26: acyl-[acyl-carrier-protein] 6-desaturase EC 1.14.19.27: sn-2 palmitoyl-lipid 9-desaturase EC 1.14.19.28: sn-1 stearoyl-lipid 9-desaturase EC 1.14.19.29: sphingolipid 8-(E/Z)-desaturase EC 1.14.19.30: acyl-lipid (8-3)-desaturase EC 1.14.19.31: acyl-lipid (7-3)-desaturase EC 1.14.19.32: palmitoyl-CoA 14-(E/Z)-desaturase EC 1.14.19.33: Δ12 acyl-lipid conjugase (11E,13E-forming) EC 1.14.19.34: acyl-lipid (9+3)-(E)-desaturase EC 1.14.19.35: sn-2 acyl-lipid ω-3 desaturase (ferredoxin) EC 1.14.19.36: sn-1 acyl-lipid ω-3 desaturase (ferredoxin) EC 1.14.19.37: acyl-CoA 5-desaturase EC 1.14.19.38: acyl-lipid Δ6-acetylenase EC 1.14.19.39: acyl-lipid Δ12-acetylenase EC 1.14.19.40: hex-5-enoyl-[acyl-carrier protein] acetylenase EC 1.14.19.41: sterol 22-desaturase EC 1.14.19.42: palmitoyl-[glycerolipid] 7-desaturase EC 1.14.19.43: palmitoyl-[glycerolipid] 3-(E)-desaturase EC 1.14.19.44: acyl-CoA (8-3)-desaturase EC 1.14.19.45: sn-1 oleoyl-lipid 12-desaturase EC 1.14.19.46: sn-1 linoleoyl-lipid 6-desaturase EC 1.14.19.47: acyl-lipid (9-3)-desaturase EC 1.14.19.48: tert-amyl alcohol desaturase EC 1.14.19.49: tetracycline 7-halogenase EC 1.14.19.50: noroxomaritidine synthase EC 1.14.19.51: (S)-corytuberine synthase EC 1.14.19.52: camalexin synthase EC 1.14.19.53: all-trans-retinol 3,4-desaturase EC 1.14.19.54: 1,2-dehydroreticuline synthase EC 1.14.19.55: 4-hydroxybenzoate brominase (decarboxylating) EC 1.14.19.56: 1H-pyrrole-2-carbonyl-[peptidyl-carrier protein] chlorinase EC 1.14.19.57: 1H-pyrrole-2-carbonyl-[peptidyl-carrier protein] brominase EC 1.14.19.58: tryptophan 5-halogenase EC 1.14.19.59: tryptophan 6-halogenase EC 1.14.19.60: 7-chloro-L-tryptophan 6-halogenase EC 1.14.19.61: dihydrorhizobitoxine desaturase EC 1.14.19.62: secologanin synthase EC 1.14.19.63: pseudobaptigenin synthase EC 1.14.19.64: (S)-stylopine synthase EC 1.14.19.65: (S)-cheilanthifoline synthase EC 1.14.19.66: berbamunine synthase EC 1.14.19.67: salutaridine synthase EC 1.14.19.68: (S)-canadine synthase EC 1.14.19.69: biflaviolin synthase EC 1.14.19.70: mycocyclosin synthase EC 1.14.19.71: fumitremorgin C synthase EC 1.14.19.72: (–)-pluviatolide synthase EC 1.14.19.73: (S)-nandinine synthase EC 1.14.19.74: (+)-piperitol/(+)-sesamin synthase EC 1.14.19.75: very-long-chain acyl-lipid ω-9 desaturase EC 1.14.19.76: flavone synthase II EC 1.14.19.77: plasmanylethanolamine desaturase EC 1.14.19.78: decanoyl-[acyl-carrier protein] acetylenase
James Eugene Carrey ( ; born January 17, 1962) is a Canadian and American actor, comedian, and visual artist. Known primarily for his energetic slapstick performances, he is regarded as one of the most prominent comedic actors of his generation. He has received two Golden Globe Awards, in addition to nominations for BAFTA Awards and Screen Actors Guild Awards. After spending the 1980s honing his comedy act and playing supporting roles in films, Carrey gained recognition when he was cast in the Fox sketch comedy series In Living Color (1990–1994). He broke out as a film star after starring in a string of box office hits, such as Ace Ventura: Pet Detective, The Mask, Dumb and Dumber (all 1994), Ace Ventura: When Nature Calls, and Batman Forever (both 1995). The success of these five films led to Carrey being the first comic actor to receive an upfront $20 million salary for performing in films, beginning with The Cable Guy (1996). Carrey continued to have success as a leading actor in comedies such as Liar Liar (1997), How the Grinch Stole Christmas (2000), Bruce Almighty (2003), Lemony Snicket's A Series of Unfortunate Events (2004), and Yes Man (2008). Since the 2010s, Carrey has appeared in fewer films, with notable works including Dumb and Dumber To (2014) and his role as Doctor Eggman in the Sonic the Hedgehog film series (2020–present). Although largely typecast as a comedic actor, Carrey had success in dramatic roles.
Cystathionine gamma lyase also shows gamma-synthase activity depending on the concentrations of reactants present. The mechanisms are the same until they diverge after formation of the vinyl glyoxylate derivative. In the gamma synthase mechanism, the gamma carbon is attacked by a sulfur nucleophile, resulting in the formation of a new sulfur-gamma carbon bond.
Many types of glucose tests exist and they can be used to estimate blood sugar levels at a given time or, over a longer period of time, to obtain average levels or to see how fast the body is able to normalize changed glucose levels. Eating food for example leads to elevated blood sugar levels. In healthy people, these levels quickly return to normal via increased cellular glucose uptake which is primarily mediated by increase in blood insulin levels. Glucose tests can reveal temporary/long-term hyperglycemia or hypoglycemia. These conditions may not have obvious symptoms and can damage organs in the long-term. Abnormally high/low levels, slow return to normal levels from either of these conditions and/or inability to normalize blood sugar levels means that the person being tested probably has some kind of medical condition like type 2 diabetes which is caused by cellular insensitivity to insulin. Glucose tests are thus often used to diagnose such conditions.
Sources: en.wikipedia.org
It separates molecules by hydrophobicity, which is effective for distinguishing an intact peptide from truncated or chemically modified forms. A C18 column with an acidic water-organic mobile phase is a standard configuration.
Lyophilised powder is generally held at minus twenty degrees Celsius or lower for long-term storage. Once dissolved, aliquots are kept at two to eight degrees Celsius for short periods and should not be repeatedly frozen and thawed.
Photo-oxidation can modify tryptophan, methionine, and tyrosine residues, altering the structure. Amber glass containers or foil wrapping are routine measures to reduce light exposure.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.